Loading
IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signalling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.61, genetic association 0.00, clinical 0.98).
In plain words · IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
IFNAR2 (Interferon alpha/beta receptor 2) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms, Leukaemia, Non-Hodgkin lymphoma and 5 more.
Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa).
No product in this corpus aims at IFNAR2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA IFNAR2: RNA low tissue specificity; no normal tissue stained high. Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms, Leukaemia, Lymphoma, Multiple myeloma, Skin cancer (all types)); Open Targets associates it with 7 specific cancer types at or above 0.5 (melanoma, acquired polycythemia vera, chronic myeloid leukemia, essential thrombocythemia, hairy cell leukemia, plasma cell myeloma and more). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas IFNAR2 tissue; Open Targets ENSG00000159110 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Novick et al, Cell, 1994, "The human interferon alpha/beta receptor: characterization and molecular cloning". Source.
Sources: HGNC HGNC:5433 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P48551 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000159110 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: melanoma 0.59, acute lymphoblastic leukaemia 0.53, B-cell chronic lymphocytic leukaemia 0.51, plasma cell myeloma 0.50, non-Hodgkin lymphoma 0.57, chronic myelogenous leukaemia, BCR-ABL1 positive 0.53 (GraphQL API, CC0))
Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signalling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (STAT1, STAT2 and STAT). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes. Potent inhibitor of type I IFN receptor activity. Location: Cell membrane; Secreted (UniProt). Locus 21q22.11 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA IFNAR2 tissue · HPA IFNAR2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"IFNAR2" OR ABSTRACT:"IFNAR2" OR TITLE:"interferon alpha and beta receptor subunit 2" OR ABSTRACT:"interferon alpha and beta receptor subunit 2" OR TITLE:"Interferon alpha/beta receptor 2" OR ABSTRACT:"Interferon alpha/beta receptor 2" OR TITLE:"IFNABR" OR ABSTRACT:"IFNABR") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IFNAR2, not a curated reading list.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Chronic myeloid leukaemia (CML), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Multiple myeloma, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Melanoma.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types), Open Targets Platform.